InvestorsHub Logo
Followers 10
Posts 1765
Boards Moderated 0
Alias Born 09/19/2019

Re: None

Wednesday, 06/30/2021 8:37:34 AM

Wednesday, June 30, 2021 8:37:34 AM

Post# of 113741
GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers

Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs

Altimmune also provides an update on its T-COVID™ Phase 1/2 Clinical Trial
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News